ClinicalTrials.gg

Program

lasofoxifene

Also written as “Lasofoxifene”, “Lasofoxifene in combination with abemaciclib” and “Lasofoxifene and abemaciclib (VERZENIO (R)).”.

Its studies are mostly in Osteoporosis · Breast Neoplasms, led by 3 companies.

Furthest: phase 3, since Aug 30, 20057 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ligand Pharmaceuticals40 open or runningphase 3since Aug 30, 2005Aug 30, 2005none ahead
Sermonix Pharmaceuticals20 open or runningphase 2since Dec 14, 2018Dec 14, 2018none ahead
LeonaBio11 open or runningphase 3since Jan 13, 2023Jan 13, 2023Apr 2027phase 3 · NCT05696626
  • Named in fosun pharma’s own pipeline as HLX78 (lasofoxifene), phase 3, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 30, 2005First study: phase 3 study in OsteoporosisNew to Ligand PharmaceuticalsLigand Pharmaceuticals · NCT00141323 · 8,556 enrolled · United States, Argentina, Australia and more
  2. Aug 31, 2005Phase 2 study in OsteoporosisLigand Pharmaceuticals · NCT00143273 · 497 enrolled · Japan, Korea, Republic of, Taiwan
  3. Sep 9, 2005Phase 3 study in OsteoporosisLigand Pharmaceuticals · NCT00163137 · 540 enrolled · United States
  4. Apr 30, 2008Phase 2 study in Bone Diseases, MetabolicLigand Pharmaceuticals · NCT00674453 · 51 enrolled · United Kingdom
  5. Dec 14, 2018Sermonix Pharmaceuticals's first study: phase 2 study in Breast NeoplasmsNew to Sermonix PharmaceuticalsSermonix Pharmaceuticals · NCT03781063 · 100 enrolled · United States, Canada, Israel
  6. Jun 4, 2020Phase 2 study in Breast NeoplasmsSermonix Pharmaceuticals · NCT04432454 · 29 enrolled · United States
  7. Jan 13, 2023LeonaBio's first study: phase 3 study in Breast NeoplasmsNew to LeonaBioLeonaBio · NCT05696626 · 600 planned · United States, Australia, Belgium and more

Ahead

  1. Apr 2027Primary completion: phase 3 study in Breast NeoplasmsLeonaBio · NCT05696626

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05696626Breast Neoplasms · United States, Australia, Belgium and more3RecruitingLeonaBioApr 2027600
NCT04432454Breast Neoplasms · United States2CompletedSermonix PharmaceuticalsJan 28, 202529
NCT03781063Breast Neoplasms · United States, Canada, Israel2CompletedSermonix PharmaceuticalsMay 8, 2025100
NCT00674453Bone Diseases, Metabolic · United Kingdom2CompletedLigand Pharmaceuticals51
NCT00163137Osteoporosis · United States3CompletedLigand PharmaceuticalsOct 2005540
NCT00143273Osteoporosis · Japan, Korea, Republic of, Taiwan2CompletedLigand PharmaceuticalsMar 2006497
NCT00141323Osteoporosis · United States, Argentina, Australia and more3CompletedLigand PharmaceuticalsDec 20078,556

How it is read

Names in the registry

  • “Lasofoxifene”, 4 entries
  • “lasofoxifene”, 4 entries
  • “Lasofoxifene in combination with abemaciclib”, 1 entry
  • “Lasofoxifene and abemaciclib (VERZENIO (R)).”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.